睿知中国疾病研究地图
候选清单0

西安西安交通大学

西安交通大学第二附属医院

Second Affiliated Hospital of Xi'an Jiaotong University

在本站收录的 53 种疾病中,这家医院列在其中 21 种下,依据是它牵头的研究论文,以及它作为牵头方或研究中心登记的试验。

这里展示的是公开记录中的研究活动,不是医疗水平评级。能否为某位患者提供帮助,应由医院和主治医生判断。

这家医院的官网还没有核对。

联系这家医院

西安交通大学第二附属医院的研究

选择一种疾病,查看背后的论文和试验。 每个方块显示 2021–2025 年牵头的论文数和每年的数量。

只包括本站收录的 53 种疾病。未列出某种疾病,表示在这些记录中这家医院没有达到该病的列出标准,不代表它不诊治该病。 哪些医院会被列出

  1. 食管鳞状细胞癌Oesophageal squamous cell carcinoma12 篇牵头论文
  2. 肝细胞癌Hepatocellular carcinoma57 篇牵头论文
  3. 胃癌Stomach cancer20 篇牵头论文
  4. 视网膜母细胞瘤Retinoblastoma2 篇牵头论文
  5. 脊索瘤Chordoma1 篇牵头论文
  6. 骨肉瘤Osteosarcoma8 篇牵头论文
  7. 神经母细胞瘤Neuroblastoma0 篇牵头论文
  8. 尤文肉瘤Ewing sarcoma1 篇牵头论文
  9. 多发性骨髓瘤Multiple myeloma17 篇牵头论文
  10. B 细胞急性淋巴细胞白血病B-cell acute lymphoblastic leukaemia0 篇牵头论文
  11. 再生障碍性贫血Aplastic anaemia0 篇牵头论文
  12. 特发性肺纤维化Idiopathic pulmonary fibrosis4 篇牵头论文
  13. 脊髓性肌萎缩症Spinal muscular atrophy4 篇牵头论文
  14. 法布雷病Fabry disease1 篇牵头论文
  15. 杜氏肌营养不良Duchenne muscular dystrophy1 篇牵头论文
  16. 白塞病Behçet disease1 篇牵头论文
  17. IgA 肾病IgA nephropathy2 篇牵头论文
  18. 原发性胆汁性胆管炎Primary biliary cholangitis2 篇牵头论文
  19. 原发性硬化性胆管炎Primary sclerosing cholangitis2 篇牵头论文
  20. 先天性巨结肠Hirschsprung disease5 篇牵头论文
  21. 遗传性血管性水肿Hereditary angioedema0 篇牵头论文

未列出的收录疾病:鼻咽癌、肝母细胞瘤、胃肠道间质瘤、噬血细胞性淋巴组织细胞增生症、β 地中海贫血、血友病 A、非典型溶血性尿毒症综合征、血栓性血小板减少性紫癜、范可尼贫血、视神经脊髓炎谱系疾病、IgG4相关性疾病、重症肌无力、烟雾病、肝豆状核变性、胆道闭锁、抗 NMDA 受体脑炎、大动脉炎、肝包虫病、肺淋巴管平滑肌瘤病、肌萎缩侧索硬化症、庞贝病、Alport 综合征、戈谢病、尼曼-匹克病 C 型、成骨不全症、先天性膈疝、遗传性大疱性表皮松解症、家族性腺瘤性息肉病、Leber 遗传性视神经病变、Majeed 综合征、NGLY1 缺乏症、ISG15 缺乏症。

癌症

食管鳞状细胞癌

Oesophageal squamous cell carcinoma

2021–2025 年中国大陆作者发表的 2,923 篇食管鳞状细胞癌 PubMed 英文论文中,这家医院牵头了 12 篇,占 0.4%。

牵头论文
12
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 3320222023: 3320232024: 4420242025: 112025

西安有 5 家医院列在食管鳞状细胞癌下全国有 191 家医院列在食管鳞状细胞癌下

截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的食管鳞状细胞癌开放试验。

这些数字背后的记录
研究主题放疗分子标志物与基因影像与人工智能
论文中的科室放疗科消化/肝病科

这些论文过半是实验室或动物研究。

牵头的论文12
  1. Comprehensive analysis of FAM83B in pan-cancer and preliminary exploration in esophageal squamous cell carcinoma.2025Journal of molecular histology
  2. Radiation-induced upregulation of FGL1 promotes esophageal squamous cell carcinoma metastasis via IMPDH1.2024BMC cancer免费全文
  3. The m6A modification of ACSL4 mRNA sensitized esophageal squamous cell carcinoma to irradiation via accelerating ferroptosis.2024Cell biology international
  4. N6-methyladenosine-mediated upregulation of LNCAROD confers radioresistance in esophageal squamous cell carcinoma through stabilizing PARP1.2024Clinical and translational medicine免费全文
  5. CD39 inhibitor (POM-1) enhances radiosensitivity of esophageal squamous cell carcinoma (ESCC) cells by promoting apoptosis through the Bax/Bcl-2/Caspase 9/Caspase 3 pathway.2024International immunopharmacology
  6. Non-acid reflux and esophageal dysmotility is associated with early esophageal squamous cell carcinoma.2023Journal of cancer research and clinical oncology免费全文
  7. Downregulation of Claudin5 promotes malignant progression and radioresistance through Beclin1-mediated autophagy in esophageal squamous cell carcinoma.2023Journal of translational medicine免费全文
  8. Hsa-miR-1269a up-regulation fosters the malignant progression of esophageal squamous cell carcinoma via targeting FAM46C.2023Mutation research
  9. CircLPAR3 knockdown suppresses esophageal squamous cell carcinoma cell oncogenic phenotypes and Warburg effect through miR-873-5p/LDHA axis.2022Human & experimental toxicology
  10. miR-4443 promotes radiation resistance of esophageal squamous cell carcinoma via targeting PTPRJ.2022Journal of translational medicine免费全文
  11. Identification and validation of an autophagy-related gene signature for predicting prognosis in patients with esophageal squamous cell carcinoma.2022Scientific reports免费全文
  12. Knockdown of TRIM15 inhibits the proliferation, migration and invasion of esophageal squamous cell carcinoma cells through inactivation of the Wnt/β-catenin signaling pathway.2021Journal of bioenergetics and biomembranes
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
  1. A Study of Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma已完成NCT03430843研究中心III期2018-01 启动
PubMed 以外找到的论文(未计入)9
  1. Preliminary results of the ALTER-E009 study: Efficacy and safety of anlotinib combined with radiotherapy in patients with locally advanced or metastatic esophageal squamous cell carcinoma (ESCC)—A multicenter, multi-cohort retrospective exp2025Journal of Clinical Oncology会议摘要
  2. Updated results of the ALTER-E00 study: Efficacy and safety of anlotinib combined with radiotherapy in patients with locally advanced or metastatic esophageal squamous cell carcinoma (ESCC): A multi-center, multi-cohort retrospective explor2025Journal of Clinical Oncology论文
  3. Additional file 2 of PES1 reduces CD8+ T cell infiltration and immunotherapy sensitivity via interrupting ILF3-IL15 complex in esophageal squamous cell carcinoma2023Figshare数据集
  4. Additional file 3 of PES1 reduces CD8+ T cell infiltration and immunotherapy sensitivity via interrupting ILF3-IL15 complex in esophageal squamous cell carcinoma2023Figshare数据集
  5. Additional file 4 of PES1 reduces CD8+ T cell infiltration and immunotherapy sensitivity via interrupting ILF3-IL15 complex in esophageal squamous cell carcinoma2023Figshare数据集
  6. Additional file 5 of PES1 reduces CD8+ T cell infiltration and immunotherapy sensitivity via interrupting ILF3-IL15 complex in esophageal squamous cell carcinoma2023Figshare数据集
  7. Hsa-miR-1269a up-regulation fosters the malignant progression of esophageal squamous cell carcinoma via targeting FAM46C2023Mutation research. Fundamental and molecular mechanisms of mutagenesis论文
  8. Corrigendum to “Decreased expression of DEAD-Box Helicase 5 inhibits esophageal squamous cell carcinomas by regulating endoplasmic reticulum stress and autophagy”2021Biochemical and Biophysical Research Communications勘误
  9. LncRNA HCP5 promotes malignant cell behaviors in esophageal squamous cell carcinoma via the PI3K/AKT/mTOR signaling2021Figshare数据集

打开 PubMed 检索ClinicalTrials.gov

癌症

肝细胞癌

Hepatocellular carcinoma

2021–2025 年中国大陆作者发表的 14,765 篇肝细胞癌 PubMed 英文论文中,这家医院牵头了 57 篇,占 0.4%。

牵头论文
57
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
1
由其他机构牵头
每年牵头的论文数
2021: 9920212022: 101020222023: 9920232024: 121220242025: 15152025

西安有 4 家医院列在肝细胞癌下全国有 192 家医院列在肝细胞癌下

这家医院参与的开放试验 1

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 即将招募
    Comparison of ultraSound, Abbreviated MRI witH and Without HBP aS mOdalities for HCC suRveillance in patienTs With High Risk
    分期
    不分期
    开始
    2025-06
    登记号
    NCT07010588

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:北京大学人民医院;另有 8 家列出的医院为研究中心北京、哈尔滨、武汉、济南、西安、重庆、长春、青岛

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题免疫与靶向药物复发与预后乙肝与肝硬化
论文中的科室普外/肝胆胰外科消化/肝病科肿瘤内科临床试验/研究机构

这些论文过半是实验室或动物研究。

牵头的论文57
  1. p57 increases immunotherapy efficacy by promoting cGAS-STING-mediated innate sensing in hepatocellular carcinoma.2026Cell reports
  2. Macrophage DHX34 as a negative regulator of the CX3CL1-CX3CR1 axis and CD8+ T-cell infiltration in hepatocellular carcinoma.2026International immunopharmacology
  3. Liver tumor imaging staging: a multi-institutional study of a preoperative staging tool for hepatocellular carcinoma.2025Abdominal radiology (New York)免费全文
  4. Gaudichaudione H Enhances the Sensitivity of Hepatocellular Carcinoma Cells to Disulfidptosis via Regulating NRF2-SLC7A11 Signaling Pathway.2025Advanced science (Weinheim, Baden-Wurttemberg, Germany)免费全文
  5. Pharmacological targeting of the mitochondrial phosphatase PTPMT1 sensitizes hepatocellular carcinoma to ferroptosis.2025Cell death & disease免费全文
  6. Deciphering the rules of disulfidptosis: a genome-wide signature for identifying disulfidptosis-related genes and analyzing hepatocellular carcinoma chemotherapy sensitivities.2025Free radical biology & medicine
  7. Alexidine dihydrochloride enhances the sensitivity of human hepatocellular carcinoma to disulfidptosis via ATF4-DDIT3 activation.2025Free radical biology & medicine
  8. Case report: A case of type 1 diabetes with diabetic ketoacidosis induced by envafolimab treatment in hepatocellular carcinoma.2025Frontiers in immunology免费全文
  9. G-Patch Domain-Containing Protein 2, Transcriptionally Activated by YY1, Facilitates the Progression of Hepatocellular Carcinoma by Boosting SNAI2 Expression.2025IUBMB life
  10. Comprehensive Pan-cancer Analysis Revealed CASP10 As a Promising Biomarker For Diverse Tumor Types.2025International journal of immunopathology and pharmacology免费全文
  11. Global Disease and Economic Burden of Noncommunicable Diseases Attributable to Hepatitis B Infection: A Health Economic Evaluation Study.2025Journal of medical virology
  12. WTAP Accelerates Exhaustion of CD8+ T Cells and Progression of Hepatocellular Carcinoma by Promoting m6A Modification and Translation of PD1 mRNA.2025Mediators of inflammation免费全文
  13. Overexpression of c-Myc triggers p62 aggregation-mediated mitochondrial mitophagy in cabozantinib resistance of hepatocellular carcinoma.2025Molecular medicine (Cambridge, Mass.)免费全文
  14. E2F1 activates USP19 to affect the stability of c-Myc to facilitate the progression of hepatocellular carcinoma.2025Mutation research
  15. DHX34 deficiency triggers tumor-intrinsic immunity via a dsRNA-mediated type I interferon pathway activation in HCC.2025Neoplasia (New York, N.Y.)免费全文
  16. Antagonism of the ATP-gated P2X7 receptor inhibits the proliferation of hepatocellular carcinoma cells.2025Purinergic signalling免费全文
  17. The contrasting regulatory effects of valproic acid on ferroptosis and disulfidptosis in hepatocellular carcinoma.2025Theranostics免费全文
  18. MRTO4 acts as an independent prognostic and immunological biomarker and is correlated with tumor microenvironment in hepatocellular carcinoma.2024Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas免费全文
  19. HOXD3 promotes the migration and angiogenesis of hepatocellular carcinoma via modifying hepatocellular carcinoma cells exosome-delivered CCR6 and regulating chromatin conformation of CCL20.2024Cell death & disease免费全文
  20. Cancer-associated fibroblasts promote the progression and chemoresistance of HCC by inducing IGF-1.2024Cellular signalling
  21. LINC00618 facilitates growth and metastasis of hepatocellular carcinoma via elevating cholesterol synthesis by promoting NSUN2-mediated SREBP2 m5C modification.2024Ecotoxicology and environmental safety
  22. FOXP2 suppresses the proliferation, invasion, and aerobic glycolysis of hepatocellular carcinoma cells by regulating the KDM5A/FBP1 axis.2024Environmental toxicology
  23. Circulating RNA ZFR promotes hepatocellular carcinoma cell proliferation and epithelial-mesenchymal transition process through miR-624-3p/WEE1 axis.2024Hepatobiliary & pancreatic diseases international : HBPD INT
  24. Exosomal circHIF1A derived from hypoxic-induced carcinoma-associated fibroblasts promotes hepatocellular carcinoma cell malignant phenotypes and immune escape.2024International immunopharmacology
  25. Chronic stress influences the macrophage M1-M2 polarization balance through β-adrenergic signaling in hepatoma mice.2024International immunopharmacology
  26. Trends in Hepatocellular Carcinoma Mortality Rates in the US and Projections Through 2040.2024JAMA network open免费全文
  27. The lncRNA lnc-TSI antagonizes sorafenib resistance in hepatocellular carcinoma via downregulating miR-4726-5p expression and upregulating KCNMA1 expression.2024Journal of molecular histology
  28. A cascade nanosystem with "Triple-Linkage" effect for enhanced photothermal and activatable metal ion therapy for hepatocellular carcinoma.2024Journal of nanobiotechnology免费全文
  29. Pan-cancer analysis and the oncogenic role of Glypican 1 in hepatocellular carcinoma.2024Scientific reports免费全文
  30. A Glucose Metabolic Intervention Nanoplatform for Enhanced Chemodynamic Therapy and Sensitized Photothermal Therapy of Hepatocellular Carcinoma.2023ACS applied materials & interfaces
  31. Cuproptosis regulatory genes greatly contribute to clinical assessments of hepatocellular carcinoma.2023BMC cancer免费全文
  32. Construction and Analysis of Hepatocellular Carcinoma Prognostic Model Based on Random Forest.2023Canadian journal of gastroenterology & hepatology免费全文
  33. Effectiveness and tolerability of camrelizumab combined with molecular targeted therapy for patients with unresectable or advanced HCC.2023Cancer immunology, immunotherapy : CII免费全文
  34. Extracellular vesicular lncRNA FAL1 promotes hepatocellular carcinoma cell proliferation and invasion by inducing macrophage M2 polarization.2023Journal of physiology and biochemistry
  35. Depletion of circ_0088046 suppressed cell growth and motility of hepatocellular carcinoma via circ_0088046-miR-1299-RTKN2 ceRNA pathway.2023Journal of viral hepatitis
  36. Circ_TEX2 Functions as a Tumor Suppressor in Hepatoma via miR-96-5p/SPRED1 Axis.2023Molecular biotechnology
  37. miR-3,178 contributes to the therapeutic action of baicalein against hepatocellular carcinoma cells via modulating HDAC10.2023Phytotherapy research : PTR
  38. Hepatoprotective effects of aspirin on diethylnitrosamine-induced hepatocellular carcinoma in rats by reducing inflammation levels and PD-L1 expression.2023Scientific reports免费全文
  39. A Meta-Analysis of Statin Use and Risk of Hepatocellular Carcinoma.2022Canadian journal of gastroenterology & hepatology免费全文
  40. Exosomal lncRNA TUG1 from cancer-associated fibroblasts promotes liver cancer cell migration, invasion, and glycolysis by regulating the miR-524-5p/SIX1 axis.2022Cellular & molecular biology letters免费全文
  41. Circ_0091579 Serves as a Tumor-Promoting Factor in Hepatocellular Carcinoma Through miR-1225-5p/PLCB1 Axis.2022Digestive diseases and sciences
  42. Circ_SNX27 regulates hepatocellular carcinoma development via miR-637/FGFR1 axis.2022Environmental toxicology
  43. LOXL3-promoted hepatocellular carcinoma progression via promotion of Snail1/USP4-mediated epithelial-mesenchymal transition.2022Environmental toxicology
  44. Aspirin Use and the Risk of Hepatocellular Carcinoma: A Meta-analysis.2022Journal of clinical gastroenterology
  45. The RNA-binding protein GRSF1 promotes hepatocarcinogenesis via competitively binding to YY1 mRNA with miR-30e-5p.2022Journal of experimental & clinical cancer research : CR免费全文
  46. Cabozantinib plus atezolizumab in advanced hepatocellular carcinoma and the role of adjuvant antiviral therapy.2022The Lancet. Oncology
  47. MicroRNA-4317 suppresses the progression of hepatocellular carcinoma by targeting ZNF436-mediated PI3K/AKT signaling pathway.2022Tissue & cell
  48. Activation of YAP1 by STK25 contributes to the progression of hepatocellular carcinoma.2022Tissue & cell
  49. The AC006262.5-miR-7855-5p-BPY2C axis facilitates hepatocellular carcinoma proliferation and migration.2021Biochemistry and cell biology = Biochimie et biologie cellulaire
  50. HIPK3 Circular RNA Promotes Metastases of HCC Through Sponging miR-338-3p to Induce ZEB2 Expression.2021Digestive diseases and sciences
  51. Saikosaponin-d increases radiation-induced apoptosis of hepatoma cells by promoting autophagy via inhibiting mTOR phosphorylation.2021International journal of medical sciences免费全文
  52. Cost-effectiveness of Atezolizumab Plus Bevacizumab vs Sorafenib for Patients With Unresectable or Metastatic Hepatocellular Carcinoma.2021JAMA network open免费全文
  53. Improved survival and high sustained virologic response with DAA therapy in patients with HCV-related HCC: A call for expanded use.2021Journal of gastroenterology and hepatology
  54. Identification of SRGAP2 as a potential oncogene and a prognostic biomarker in hepatocellular carcinoma.2021Life sciences
  55. Long non‑coding RNA LOC284454 promotes hepatocellular carcinoma cell invasion and migration by inhibiting E‑cadherin expression.2021Oncology reports
  56. Circ_0046600 promotes hepatocellular carcinoma progression via up-regulating SERBP1 through sequestering miR-1258.2021Pathology, research and practice
  57. MiR-3663-3p participates in the anti-hepatocellular carcinoma proliferation activity of baicalein by targeting SH3GL1 and negatively regulating EGFR/ERK/NF-κB signaling.2021Toxicology and applied pharmacology
它在 ClinicalTrials.gov 上的全部试验(任何状态)2
  1. Comparison of ultraSound, Abbreviated MRI witH and Without HBP aS mOdalities for HCC suRveillance in patienTs With High Risk即将招募NCT07010588研究中心不分期2025-06 启动
  2. Effect and Safety of Recombinant Human Adenovirus Type 5 in Advanced HCC With Stable Disease After Sorafenib Treatment状态不明NCT05113290研究中心IV期2021-12 启动

打开 PubMed 检索ClinicalTrials.gov

癌症

胃癌

Stomach cancer

2021–2025 年中国大陆作者发表的 9,782 篇胃癌 PubMed 英文论文中,这家医院牵头了 20 篇,占 0.2%。

牵头论文
20
2021–2025 年
牵头试验
1
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
1
由其他机构牵头
每年牵头的论文数
2021: 7720212022: 2220222023: 2220232024: 7720242025: 222025

西安有 7 家医院列在胃癌下全国有 218 家医院列在胃癌下

这家医院参与的开放试验 1

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Clinical Study of Taurine Combined With Neoadjuvant Chemo-Immunotherapy for Treatment of Locally Advanced Gastric Cancer
    分期
    不分期
    开始
    2024-09
    登记号
    NCT06128252

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:空军军医大学唐都医院;另有 11 家列出的医院为研究中心上海、乌鲁木齐、南京、武汉、沈阳、西安、重庆

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题早期发现与内镜影像与人工智能营养与康复
论文中的科室消化/肝病科肿瘤内科普外/肝胆胰外科耳鼻喉/头颈外科

这些论文过半是实验室或动物研究。

牵头的论文20
  1. The role of indocyanine green in the intraoperative navigation of gastric cancer surgery: a systematic review and meta-analysis.2025BMC cancer免费全文
  2. Best practices for home nutritional management in postoperative gastric cancer patients: an evidence summary.2025BMC cancer免费全文
  3. The staining results of early gastric cancer by indigo carmine chromoendoscopy associated with histological structure: a retrospective study.2024BMC cancer免费全文
  4. Downregulation of lncRNA EPB41L4A-AS1 promotes gastric cancer cell proliferation, migration and invasion.2024BMC gastroenterology免费全文
  5. MyoD1 promotes the transcription of BIK and plays an apoptosis-promoting role in the development of gastric cancer.2024Cell cycle (Georgetown, Tex.)免费全文
  6. Cinnamaldehyde Regulates the Migration and Apoptosis of Gastric Cancer Cells by Inhibiting the Jak2/Stat3 Pathway.2024Digestive diseases and sciences
  7. FUT3 promotes gastric cancer cell migration by synthesizing Lea on ITGA6 and GLG1, affecting adhesion and vesicle distribution.2024Life sciences
  8. Synergistic Effects of Matrix Biophysical Properties on Gastric Cancer Cell Behavior via Integrin-Mediated Cell-ECM Interactions.2024Small (Weinheim an der Bergstrasse, Germany)
  9. Characteristics of early gastric tumors with different differentiation and predictors of long-term outcomes after endoscopic submucosal dissection.2024World journal of gastroenterology免费全文
  10. Emphasis on the clinical relationship between alpha-fetoprotein and hepatoid adenocarcinoma of the stomach: a retrospective study.2023BMC gastroenterology免费全文
  11. Causal effects of COVID-19 on cancer risk: A Mendelian randomization study.2023Journal of medical virology
  12. LncRNA-p21 suppresses cell proliferation and induces apoptosis in gastric cancer by sponging miR-514b-3p and up-regulating ARHGEF9 expression.2022Biological chemistry
  13. BMP2 inhibits cell proliferation by downregulating EZH2 in gastric cancer.2022Cell cycle (Georgetown, Tex.)免费全文
  14. Magnetic multidirectional anchor-guided endoscopic submucosal tunnel dissection for large gastric lesions.2021Endoscopy
  15. Critical role of miR-26a-5p/Wnt5a signaling in gambogic acid-induced inhibition of gastric cancer.2021Journal of biochemical and molecular toxicology
  16. Snapshot polarized light scattering spectroscopy using spectrally-modulated polarimetry for early gastric cancer detection.2021Journal of biophotonics
  17. ARL4C might serve as a prognostic factor and a novel therapeutic target for gastric cancer: bioinformatics analyses and biological experiments.2021Journal of cellular and molecular medicine免费全文
  18. Identification of core genes and clinical outcomes in tumors originated from endoderm (gastric cancer and lung carcinoma) via bioinformatics analysis.2021Medicine免费全文
  19. Retinoblastoma tumor suppressor gene 1 enhances 5-Fluorouracil chemosensitivity through SDF-1/CXCR4 axis by regulating autophagy in gastric cancer.2021Pathology, research and practice
  20. Identification of novel antioxidant gene signature to predict the prognosis of patients with gastric cancer.2021World journal of surgical oncology免费全文
它在 ClinicalTrials.gov 上的全部试验(任何状态)2
  1. Screening for Early Gastric Cancer in Shaanxi Province状态不明NCT05291728牵头方2020-10 启动
  2. Clinical Study of Taurine Combined With Neoadjuvant Chemo-Immunotherapy for Treatment of Locally Advanced Gastric Cancer正在招募NCT06128252研究中心不分期2024-09 启动

打开 PubMed 检索ClinicalTrials.gov

癌症

视网膜母细胞瘤

Retinoblastoma

2021–2025 年中国大陆作者发表的 301 篇视网膜母细胞瘤 PubMed 英文论文中,这家医院牵头了 2 篇,占 0.7%。

牵头论文
2
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 0020222023: 0020232024: 0020242025: 112025

西安有 12 家医院列在视网膜母细胞瘤下全国有 196 家医院列在视网膜母细胞瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的视网膜母细胞瘤开放试验。

这些数字背后的记录
论文中的科室消化/肝病科

打开 PubMed 检索ClinicalTrials.gov

癌症

脊索瘤

Chordoma

2021–2025 年中国大陆作者发表的 105 篇脊索瘤 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.9%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 0020222023: 0020232024: 0020242025: 002025

西安有 5 家医院列在脊索瘤下全国有 88 家医院列在脊索瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的脊索瘤开放试验。

这些数字背后的记录
论文中的科室耳鼻喉/头颈外科

打开 PubMed 检索ClinicalTrials.gov

癌症

骨肉瘤

Osteosarcoma

2021–2025 年中国大陆作者发表的 2,257 篇骨肉瘤 PubMed 英文论文中,这家医院牵头了 8 篇,占 0.4%。

牵头论文
8
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 2220222023: 3320232024: 1120242025: 222025

西安有 27 家医院列在骨肉瘤下全国有 742 家医院列在骨肉瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的骨肉瘤开放试验。

这些数字背后的记录

这些论文过半是实验室或动物研究。

牵头的论文8
  1. Bone-Adhesive Peptide Hydrogel Loaded with Cisplatin for Postoperative Treatment of Osteosarcoma.2025ACS applied materials & interfaces
  2. PDK1-mediated phosphorylation of USP5 modulates NF-κB signalling to enhance osteosarcoma growth.2025International journal of biological macromolecules
  3. MiR-383 sensitizes osteosarcoma cells to bortezomib treatment via down-regulating PSMB5.2024Molecular biology reports
  4. ZIM3 activation of CCL25 expression in pulmonary metastatic nodules of osteosarcoma recruits M2 macrophages to promote metastatic growth.2023Cancer immunology, immunotherapy : CII
  5. SIX4 upregulates IDH1 and metabolic reprogramming to promote osteosarcoma progression.2023Journal of cellular and molecular medicine
  6. MUC1 promotes cancer stemness and predicts poor prognosis in osteosarcoma.2023Pathology, research and practice
  7. A tool for predicting overall survival in patients with Ewing sarcoma: a multicenter retrospective study.2022BMC cancer
  8. Osteosarcoma exocytosis of soluble LGALS3BP mediates macrophages toward a tumoricidal phenotype.2022Cancer letters
中文论文(未计入)1
  1. [miRNA-181a-5p inhibits proliferation and migration of osteosarcoma cell line HOS by targeting HOXB4].2022Zhongguo gu shang = China journal of orthopaedics and traumatology
早期论文(2016–2020 年)14
  1. MicroRNA-211-5p promotes apoptosis and inhibits the migration of osteosarcoma cells by targeting proline-rich protein PRR11.2020Biochemistry and cell biology = Biochimie et biologie cellulaire
  2. Long noncoding RNA PWRN1 is lowly expressed in osteosarcoma and modulates cancer proliferation and migration by targeting hsa-miR-214-5p.2020IUBMB life
  3. Nomograms for predicting overall survival and cancer-specific survival of chondroblastic osteosarcoma patients.2020Journal of surgical oncology
  4. Downregulation of Cdc6 inhibits tumorigenesis of osteosarcoma in vivo and in vitro.2019Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
  5. The induction of ferroptosis by impairing STAT3/Nrf2/GPx4 signaling enhances the sensitivity of osteosarcoma cells to cisplatin.2019Cell biology international
  6. Integrative analysis reveals driver long non-coding RNAs in osteosarcoma.2019Medicine
  7. Notch signaling regulates osteosarcoma proliferation and migration through Erk phosphorylation.2019Tissue & cell
  8. MiR-30a-5p inhibits osteosarcoma cell proliferation and migration by targeting FOXD1.2018Biochemical and biophysical research communications
  9. MicroRNA‑22 inhibits the proliferation and migration, and increases the cisplatin sensitivity, of osteosarcoma cells.2018Molecular medicine reports
  10. GPNMB silencing suppresses the proliferation and metastasis of osteosarcoma cells by blocking the PI3K/Akt/mTOR signaling pathway.2018Oncology reports
  11. Predicting novel genes and pathways associated with osteosarcoma by using bioinformatics analysis.2017Gene
  12. Emodin Impairs Radioresistance of Human Osteosarcoma Cells by Suppressing Sonic Hedgehog Signaling.2017Medical science monitor : international medical journal of experimental and clinical research
  13. Fibroblast growth factor receptor 1 promotes MG63 cell proliferation and is associated with increased expression of cyclin-dependent kinase 1 in osteosarcoma.2016Molecular medicine reports
  14. Combined over-expression of the hypoxia-inducible factor 2α gene and its long non-coding RNA predicts unfavorable prognosis of patients with osteosarcoma.2016Pathology, research and practice

打开 PubMed 检索ClinicalTrials.gov

癌症

神经母细胞瘤

Neuroblastoma

2021–2025 年没有牵头神经母细胞瘤的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

西安有 13 家医院列在神经母细胞瘤下全国有 352 家医院列在神经母细胞瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的神经母细胞瘤开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

癌症

尤文肉瘤

Ewing sarcoma

2021–2025 年中国大陆作者发表的 163 篇尤文肉瘤 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.6%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 1120222023: 0020232024: 0020242025: 002025

西安有 4 家医院列在尤文肉瘤下全国有 139 家医院列在尤文肉瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的尤文肉瘤开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

血液疾病

多发性骨髓瘤

Multiple myeloma

2021–2025 年中国大陆作者发表的 1,676 篇多发性骨髓瘤 PubMed 英文论文中,这家医院牵头了 17 篇,占 1.0%。

牵头论文
17
2021–2025 年
牵头试验
3
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
10
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 3320222023: 5520232024: 6620242025: 222025

西安有 4 家医院列在多发性骨髓瘤下全国有 178 家医院列在多发性骨髓瘤下

这家医院参与的开放试验 10

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
    分期
    III期
    开始
    2026-02
    登记号
    NCT07258511

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 9 家列出的医院为研究中心北京、南京、南宁、成都、杭州、武汉、温州、西安

  2. 正在招募
    To Evaluate the Safety of SG2918 in Patients With Relapsed/Refractory Multiple Myeloma
    分期
    I/II期
    开始
    2026-04
    登记号
    NCT07454187

    年龄 18 岁 至 80 岁(登记的条件)

    牵头方不是列出的医院;另有 4 家列出的医院为研究中心杭州、苏州、西安、郑州

  3. 正在招募
    A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
    分期
    III期
    开始
    2026-05
    登记号
    NCT07518186

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 14 家列出的医院为研究中心北京、南京、南昌、天津、成都、杭州、武汉、深圳、温州、西安、长春

  4. 正在招募
    A Clinical Study to Evaluate LVIVO-TaVec200 for the Treatment of Relapsed/Refractory Multiple Myeloma
    分期
    早期I期
    开始
    2025-12
    登记号
    NCT07294625

    年龄 18 岁 至 未注明(登记的条件)

    牵头:江苏省人民医院(南医大一附院);另有 4 家列出的医院为研究中心上海、南京、徐州、西安、郑州

  5. 正在招募
    A Clinical Study Comparing SG301 Plus Pomalidomide and Dexamethasone to Placebo Plus Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma Patients
    分期
    III期
    开始
    2024-06
    登记号
    NCT06508983

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 9 家列出的医院为研究中心北京、天津、广州、杭州、武汉、苏州、西安、郑州

  6. 正在招募
    A Clinical Trial of LBL-034 in Patients With Relapsed Refractory Multiple Myeloma
    分期
    I/II期
    开始
    2023-10
    登记号
    NCT06049290

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 19 家列出的医院为研究中心上海、北京、厦门、太原、宁波、广州、杭州、武汉、沈阳、海口、深圳、温州、苏州、西安、贵阳、郑州、长春、青岛

  7. 正在招募
    A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
    分期
    IV期
    开始
    2022-03
    登记号
    NCT05201781

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 10 家列出的医院为研究中心上海、北京、南京、广州、成都、杭州、福州、西安

  8. 正在招募
    A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
    分期
    III期
    开始
    2022-10
    登记号
    NCT05552222

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 29 家列出的医院为研究中心上海、北京、南京、南宁、南昌、厦门、哈尔滨、天津、常州、广州、成都、杭州、武汉、沈阳、济南、深圳、温州、福州、西安、郑州、重庆、长春、长沙

  9. 正在招募
    A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma
    分期
    II期
    开始
    2021-02
    登记号
    NCT04634552

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 5 家列出的医院为研究中心北京、天津、苏州、西安

  10. 即将招募
    Clinical Study of TQB2934 Injection in Relapsed/Refractory Multiple Myeloma
    分期
    III期
    开始
    2026-06
    登记号
    NCT07569757

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 38 家列出的医院为研究中心上海、兰州、北京、南京、南宁、南昌、合肥、哈尔滨、太原、广州、徐州、成都、承德、昆明、杭州、株洲、沈阳、泸州、济南、湛江、石家庄、蚌埠、西安、贵阳、郑州、重庆、长沙、青岛

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题诊断、微小残留病与危险分层CAR-T 与细胞治疗复发与耐药
论文中的科室病理/检验科
牵头的论文17
  1. Efficacy and safety of anti-CD38 monoclonal antibodies in patients with newly diagnosed multiple myeloma: an updated systematic review and meta-analysis based on randomized controlled trials.2025Leukemia & lymphoma
  2. Peroxiredoxin 6 maintains mitochondrial homeostasis and promotes tumor progression through ROS/JNK/p38 MAPK signaling pathway in multiple myeloma.2025Scientific reports免费全文
  3. Outcomes in patients with multiple myeloma receiving salvage treatment after BCMA-specific CAR-T therapy: A retrospective analysis of LEGEND-2.2024British journal of haematology
  4. Circular RNA circXPO1 Promotes Multiple Myeloma Progression by Regulating miR-495-3p/DNA Damage-Induced Transcription 4 Axis.2024DNA and cell biology免费全文
  5. Mitochondria-associated programmed cell death: elucidating prognostic biomarkers, immune checkpoints, and therapeutic avenues in multiple myeloma.2024Frontiers in immunology免费全文
  6. The significance of RB1 in multiple myeloma.2024Frontiers in immunology免费全文
  7. Mechanisms and salvage treatments in patients with multiple myeloma relapsed post-BCMA CAR-T cell therapy.2024Frontiers in immunology免费全文
  8. KIF22 promotes multiple myeloma progression by regulating the CDC25C/CDK1/cyclinB1 pathway.2024Journal of cancer research and clinical oncology免费全文
  9. Integrative analysis of the prognostic value and immune microenvironment of mitophagy-related signature for multiple myeloma.2023BMC cancer免费全文
  10. PRMT1 methylation of WTAP promotes multiple myeloma tumorigenesis by activating oxidative phosphorylation via m6A modification of NDUFS6.2023Cell death & disease免费全文
  11. Serum soluble BCMA can be used to monitor relapse of multiple myeloma patients after chimeric antigen receptor T-cell immunotherapy.2023Current research in translational medicine
  12. A comprehensive analysis of coagulopathy during anti-B cell maturation antigen chimeric antigen receptor-T therapy in multiple myeloma, a retrospective study based on LEGEND-2.2023Hematological oncology
  13. N6-methyladenosine reader YTHDF2 promotes multiple myeloma cell proliferation through EGR1/p21cip1/waf1/CDK2-Cyclin E1 axis-mediated cell cycle transition.2023Oncogene免费全文
  14. Importance of circulating adipocytokines in multiple myeloma: a systematic review and meta-analysis based on case-control studies.2022BMC endocrine disorders免费全文
  15. Four-year follow-up of LCAR-B38M in relapsed or refractory multiple myeloma: a phase 1, single-arm, open-label, multicenter study in China (LEGEND-2).2022Journal of hematology & oncology免费全文
  16. Five-year remission without disease progression in a patient with relapsed/refractory multiple myeloma with extramedullary disease treated with LCAR-B38M chimeric antigen receptor T cells in the LEGEND-2 study: a case report.2022Journal of medical case reports免费全文
  17. lncRNA ST3GAL6‑AS1 promotes invasion by inhibiting hnRNPA2B1‑mediated ST3GAL6 expression in multiple myeloma.2021International journal of oncology免费全文
中文论文(未计入)1
  1. [Alteration and significance of serum lipid levels and nutritional status during BCMA-CAR-T-cell therapy in patients with refractory or relapsed multiple myeloma: a retrospective study based on LEGEND-2].2023Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi免费全文
它在 ClinicalTrials.gov 上的全部试验(任何状态)21
  1. Universal BCMA-targeted LUCAR-B68 Cells in Patients With Relapsed/Refractory Multiple Myeloma已终止NCT05498545牵头方I期2022-11 启动
  2. CAR-T Re-treatment for Refractory/Relapsed Multiple Myeloma状态不明NCT03672253牵头方I期2018-07 启动
  3. LCAR-B4822M-02 Cells in Treating Relapsed/Refractory (R/R) Multiple Myeloma状态不明NCT03674463牵头方I期2018-07 启动
  4. A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma正在招募NCT07518186研究中心III期2026-05 启动
  5. To Evaluate the Safety of SG2918 in Patients With Relapsed/Refractory Multiple Myeloma正在招募NCT07454187研究中心I/II期2026-04 启动
  6. A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma正在招募NCT07258511研究中心III期2026-02 启动
  7. Clinical Study of TQB2934 Injection in Relapsed/Refractory Multiple Myeloma即将招募NCT07569757研究中心III期2026-06 启动
  8. A Clinical Study to Evaluate LVIVO-TaVec200 for the Treatment of Relapsed/Refractory Multiple Myeloma正在招募NCT07294625研究中心早期I期2025-12 启动
  9. A Clinical Study Comparing SG301 Plus Pomalidomide and Dexamethasone to Placebo Plus Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma Patients正在招募NCT06508983研究中心III期2024-06 启动
  10. A Clinical Trial of LBL-034 in Patients With Relapsed Refractory Multiple Myeloma正在招募NCT06049290研究中心I/II期2023-10 启动
  11. A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel正在招募NCT05201781研究中心IV期2022-03 启动
  12. A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma正在招募NCT05552222研究中心III期2022-10 启动
  13. A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma正在招募NCT04634552研究中心II期2021-02 启动
  14. A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide进行中,不再招募NCT06208150研究中心III期2024-01 启动
  15. Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma进行中,不再招募NCT06158841研究中心III期2024-05 启动
  16. A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma进行中,不再招募NCT05572515研究中心III期2023-03 启动
  17. A Study of the Efficacy and Safety of Pomalidomide Capsules Combined With Low-Dose Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma状态不明NCT05236621研究中心III期2021-01 启动
  18. ATG-010(Selinexor) in Combination With Chemotherapy in RRMM状态不明NCT04877275研究中心II期2021-05 启动
  19. A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma进行中,不再招募NCT05083169研究中心III期2021-10 启动
  20. A Study of Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma进行中,不再招募NCT04557098研究中心II期2020-09 启动
  21. A Study of LCAR-B38M CAR-T Cells, a Chimeric Antigen Receptor T-cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Chinese Participants With Relapsed or Refractory Multiple Myeloma已终止NCT03758417研究中心II期2019-01 启动

打开 PubMed 检索ClinicalTrials.gov

血液疾病

B 细胞急性淋巴细胞白血病

B-cell acute lymphoblastic leukaemia

2021–2025 年没有牵头B 细胞急性淋巴细胞白血病的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
1
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

西安有 4 家医院列在B 细胞急性淋巴细胞白血病下全国有 90 家医院列在B 细胞急性淋巴细胞白血病下

截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的B 细胞急性淋巴细胞白血病开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

血液疾病

再生障碍性贫血

Aplastic anaemia

2021–2025 年没有牵头再生障碍性贫血的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

西安有 1 家医院列在再生障碍性贫血下全国有 63 家医院列在再生障碍性贫血下

截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的再生障碍性贫血开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

其他疾病

特发性肺纤维化

Idiopathic pulmonary fibrosis

2021–2025 年中国大陆作者发表的 989 篇特发性肺纤维化 PubMed 英文论文中,这家医院牵头了 4 篇,占 0.4%。

牵头论文
4
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
1
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 1120222023: 1120232024: 0020242025: 112025

西安有 12 家医院列在特发性肺纤维化下全国有 333 家医院列在特发性肺纤维化下

这家医院参与的开放试验 1

依据 ClinicalTrials.gov 在 2026年11月13日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Study Evaluation Rentosertib (INS018_055) Administered Orally in Patients With Idiopathic Pulmonary Fibrosis (IPF)
    分期
    III期
    开始
    2026-09
    登记号
    NCT07687459

    年龄 40 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 45 家列出的医院为研究中心Yuncheng、上海、乌鲁木齐、北京、南京、南宁、南昌、南阳、厦门、合肥、呼和浩特、天津、太原、宁波、宜昌、广州、徐州、成都、昆明、杭州、武汉、沈阳、济南、海口、温州、石家庄、福州、西安、郑州、长春、长沙

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

其他疾病

脊髓性肌萎缩症

Spinal muscular atrophy

2021–2025 年中国大陆作者发表的 55 篇脊髓性肌萎缩症 PubMed 英文论文中,这家医院牵头了 4 篇,占 7.3%。

牵头论文
4
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 3320242025: 112025

西安有 1 家医院列在脊髓性肌萎缩症下全国有 51 家医院列在脊髓性肌萎缩症下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的脊髓性肌萎缩症开放试验。

这些数字背后的记录
论文中的科室儿科

打开 PubMed 检索ClinicalTrials.gov

其他疾病

法布雷病

Fabry disease

2021–2025 年中国大陆作者发表的 73 篇法布雷病 PubMed 英文论文中,这家医院牵头了 1 篇,占 1.4%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
1
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 1120242025: 002025

西安有 3 家医院列在法布雷病下全国有 85 家医院列在法布雷病下

这家医院参与的开放试验 1

依据 ClinicalTrials.gov 在 2026年11月13日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    A Study of Agalsidase Alfa Enyzme Replacement Therapy in Chinese Children and Adults With Fabry Disease
    分期
    未注明
    开始
    2025-11
    登记号
    NCT07187440

    年龄 7 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 18 家列出的医院为研究中心北京、南京、合肥、哈尔滨、天津、太原、成都、杭州、汕头、深圳、石家庄、福州、苏州、西安

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
牵头的论文1
  1. Hemoporfin-mediated photodynamic therapy for angiokeratoma corporis diffusum: A case report.2024Photodiagnosis and photodynamic therapy
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
  1. A Study of Agalsidase Alfa Enyzme Replacement Therapy in Chinese Children and Adults With Fabry Disease正在招募NCT07187440研究中心2025-11 启动

打开 PubMed 检索ClinicalTrials.gov

其他疾病

杜氏肌营养不良

Duchenne muscular dystrophy

2021–2025 年中国大陆作者发表的 213 篇杜氏肌营养不良 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.5%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 0020222023: 0020232024: 0020242025: 002025

西安有 4 家医院列在杜氏肌营养不良下全国有 116 家医院列在杜氏肌营养不良下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的杜氏肌营养不良开放试验。

这些数字背后的记录
论文中的科室儿科
牵头的论文1
  1. An anti-ADAMTS1 treatment relieved muscle dysfunction and fibrosis in dystrophic mice.2021Life sciences
早期论文(2016–2020 年)1
  1. Identification of Hub Genes in Duchenne Muscular Dystrophy: Evidence from Bioinformatic Analysis.2020Journal of computational biology : a journal of computational molecular cell biology

打开 PubMed 检索ClinicalTrials.gov

其他疾病

白塞病

Behçet disease

2021–2025 年中国大陆作者发表的 245 篇白塞病 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.4%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 1120242025: 002025

西安有 3 家医院列在白塞病下全国有 149 家医院列在白塞病下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的白塞病开放试验。

这些数字背后的记录
论文中的科室消化/肝病科

打开 PubMed 检索ClinicalTrials.gov

其他疾病

IgA 肾病

IgA nephropathy

2021–2025 年中国大陆作者发表的 736 篇IgA 肾病 PubMed 英文论文中,这家医院牵头了 2 篇,占 0.3%。

牵头论文
2
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 1120222023: 0020232024: 1120242025: 002025

西安有 10 家医院列在IgA 肾病下全国有 346 家医院列在IgA 肾病下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的IgA 肾病开放试验。

这些数字背后的记录
论文中的科室肾内科

打开 PubMed 检索ClinicalTrials.gov

其他疾病

原发性胆汁性胆管炎

Primary biliary cholangitis

2021–2025 年中国大陆作者发表的 300 篇原发性胆汁性胆管炎 PubMed 英文论文中,这家医院牵头了 2 篇,占 0.7%。

牵头论文
2
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 1120222023: 0020232024: 1120242025: 002025

西安有 8 家医院列在原发性胆汁性胆管炎下全国有 173 家医院列在原发性胆汁性胆管炎下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的原发性胆汁性胆管炎开放试验。

这些数字背后的记录
论文中的科室消化/肝病科

打开 PubMed 检索ClinicalTrials.gov

其他疾病

原发性硬化性胆管炎

Primary sclerosing cholangitis

2021–2025 年中国大陆作者发表的 100 篇原发性硬化性胆管炎 PubMed 英文论文中,这家医院牵头了 2 篇,占 2.0%。

牵头论文
2
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 2220242025: 002025

西安有 4 家医院列在原发性硬化性胆管炎下全国有 90 家医院列在原发性硬化性胆管炎下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的原发性硬化性胆管炎开放试验。

这些数字背后的记录
论文中的科室消化/肝病科

打开 PubMed 检索ClinicalTrials.gov

其他疾病

先天性巨结肠

Hirschsprung disease

2021–2025 年中国大陆作者发表的 161 篇先天性巨结肠 PubMed 英文论文中,这家医院牵头了 5 篇,占 3.1%。

牵头论文
5
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 2220222023: 1120232024: 1120242025: 002025

西安有 3 家医院列在先天性巨结肠下全国有 82 家医院列在先天性巨结肠下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的先天性巨结肠开放试验。

这些数字背后的记录
论文中的科室儿科

这些论文过半是实验室或动物研究。

牵头的论文5
  1. Sodium butyrate promotes enteric glial cells neurogenesis by inhibiting Kdm2a and inducing Klf4 expression.2026Journal of pediatric surgery
  2. Autologous cell transplantation for treatment of colorectal aganglionosis in mice.2024Nature communications
  3. Fecal microbiota transplantation enhances cell therapy in a rat model of hypoganglionosis by SCFA-induced MEK1/2 signaling pathway.2023The EMBO journal
  4. Opportunities for novel diagnostic and cell-based therapies for Hirschsprung disease.2022Journal of pediatric surgery
  5. Schwann Cells in the Aganglionic Colon of Hirschsprung Disease Can Generate Neurons for Regenerative Therapy.2022Stem cells translational medicine
早期论文(2016–2020 年)8
  1. Involvement of the lncRNA AFAP1-AS1/microRNA-195/E2F3 axis in proliferation and migration of enteric neural crest stem cells of Hirschsprung's disease.2020Experimental physiology
  2. Inhibition of ROCK signaling pathway accelerates enteric neural crest cell-based therapy after transplantation in a rat hypoganglionic model.2020Neurogastroenterology and motility
  3. Correlation of spatio-temporal characteristics of intestinal inflammation with IL-17 in a rat model of hypoganglionosis.2018Biochemical and biophysical research communications
  4. Combination of exogenous cell transplantation and 5-HT4 receptor agonism induce endogenous enteric neural crest-derived cells in a rat hypoganglionosis model.2017Experimental cell research
  5. Upregulation of MiR-369-3p suppresses cell migration and proliferation by targeting SOX4 in Hirschsprung's disease.2017Journal of pediatric surgery
  6. Investigation of the expression of apoptosis-inducing factor-mediated apoptosis in Hirschsprung's disease.2017Neuroreport
  7. Identifying key genes associated with Hirschsprung's disease based on bioinformatics analysis of RNA-sequencing data.2017World journal of pediatrics : WJP
  8. A Time-Limited and Partially Reversible Model of Hypoganglionosis Induced by Benzalkonium Chloride Treatment.2016Neurochemical research

打开 PubMed 检索ClinicalTrials.gov

其他疾病

遗传性血管性水肿

Hereditary angioedema

2021–2025 年没有牵头遗传性血管性水肿的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

西安有 1 家医院列在遗传性血管性水肿下全国有 30 家医院列在遗传性血管性水肿下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的遗传性血管性水肿开放试验。

这些数字背后的记录
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
  1. A Study of Lanadelumab (Takhzyro) and Icatibant (Firazyr®) in Persons With HAE in China已完成NCT06346899研究中心2024-07 启动

打开 PubMed 检索ClinicalTrials.gov

联系这家医院

出示给工作人员或司机的院名卡

西安交通大学第二附属医院

Second Affiliated Hospital of Xi'an Jiaotong University

西安

大医院往往有多个院区,出发前请先向医院确认院区。

中英对照的咨询信

填写方括号中的内容后,通过医院国际医疗部或官网上的联系方式发送。在这里输入的内容不会离开您的设备。

医院通常需要的资料

  • 主治医生近期的病情总结或信件
  • 病理报告
  • 影像检查(CT、MRI、PET)及报告,尽量附影像文件
  • 已接受的治疗及时间
  • 目前用药

下一步建议

与主治医生沟通可将本页分享给主治医生,一同评估该团队的研究方向是否相关。
确认团队现状论文发表通常滞后数月,医生也可能调动。请在医院官网查询相关科室。
直接联系医院请通过医院官方公布的渠道联系。医院不向我们支付任何费用;是否接诊由医院决定。

这些数字从哪里来

论文

2021–2025 年 PubMed 英文论文中,第一作者或最后作者的第一单位是这家医院的论文。 定义

试验

ClinicalTrials.gov 上列出这家医院为牵头方或研究中心的记录,截至 2026年11月8日。

编号与其他名称

ROR Wikidata
Second Affiliated Hospital of Xi'an Jiao Tong University; Second Affiliated Hospital of Xi'an JiaoTong University; Second Affiliated Hospital of Xian Jiaotong University

提出更正下载数据